SITC Updates

JITC Digest July 2026

By JITC Publications posted yesterday

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|New Special Series Myeloid Cells in Immuno-Oncology| JITC Meet-the-Editor Seession at JACI (Japan)| Popular Articles Letter from the Editor Hello JITC Readers, This month I would like to call attention to the recently completed “ Myeloid Cells in Immuno-Oncology ” special series now out in JITC . We also have several exciting series in the works which will be appearing over the next few months, including ones on AI in IO and neurobiology/immunobiology intersections. Myeloid Cells in Cancer Immunology Cancer in adults (but not ...

Oncology News Burst from the FDA: FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By SITC Communications posted 3 days ago

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

SITC Raises Concerns About Proposed Changes to Federal Grant-Making Rules

By SITC Advocacy posted 8 days ago

The Society for Immunotherapy of Cancer (SITC) has submitted comments to the Office of Management and Budget (OMB) regarding proposed changes to the regulations governing Federal Financial Assistance . View the comments in their entirety at this LINK . For decades, independent scientific peer review has ensured that federal research funding is awarded based on scientific merit, innovation, and potential patient benefit. This merit-based system has helped drive groundbreaking advances in cancer research and established the United States as a global leader in biomedical innovation. SITC is concerned that the proposed rule could reduce the role ...

Oncology News Burst from the FDA: FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor Hematopoietic Stem Cell Transplantation for Adults with Hematologic Malignancies

By SITC Communications posted 14 days ago

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Immune Monitor - June 2026

By SITC Communications posted 15 days ago

A Message from the President As Cancer Immunotherapy Awareness Month comes to a close, I’m reflecting on the remarkable progress and momentum in the field of cancer immuno-oncology. Throughout June, our community celebrated the scientific advances, collaboration and innovation that are shaping the future of cancer treatment, and I am proud of the many ways SITC helped elevate and support these important conversations. Just last week, SITC hosted the 2026 Biotech Strategic Meeting at the New York Stock Exchange, where we set the stage for critical conversations on investing, financing, international drug development and other strategic considerations ...

Oncology News Burst from the FDA: FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of Triple-Negative Breast Cancer

By SITC Communications posted 15 days ago

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Oncology News Burst from the FDA: FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of renal cell carcinoma

By SITC Communications posted 16 days ago

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

JITC Digest June 2026

By JITC Publications posted 28 days ago

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|SITC 40 th Anniversary Special Series| Popular Articles Letter from the Editor Hello JITC Readers, June is Cancer Immunotherapy Month—a time to celebrate the remarkable progress our field has achieved and recommit ourselves to the work that remains. As we celebrate this month, I am delighted to share JITC’s new 2025 Impact Factor of 11.7—an outstanding achievement that shows the continued strength, influence, and growth of our journal, and places JITC among the top 5% of all immunology journals and the top 9% of all oncology journals. It ...

2026 ASCO Annual Meeting Scientific Highlights - June 2

By Thomas Martin posted 06-03-2026

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 2, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Fitness-enhanced CEA-targeting CAR T cells for advanced colorectal cancer with peritoneal metastases 3514. Phase 1 study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR T cells in advanced colorectal cancer with peritoneal metastases Hangyu Zhang (The First Affiliate Hospital, Zhejiang University School of Medicine, Hangzhou, China) presented safety and preliminary efficacy data from ...

2026 ASCO Annual Meeting Scientific Highlights - June 1

By Thomas Martin posted 06-02-2026

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 1, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Live biotherapeutic CBM588 improves the clinical efficacy of immune checkpoint blockade-based therapies as first-line treatment for metastatic renal cell carcinoma 4519. Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade-based first line therapies in metastatic renal cell carcinoma Rahul Winayak (City of Hope Comprehensive Cancer Center, Duarte, ...

2026 ASCO Annual Meeting Scientific Highlights - May 31

By Thomas Martin posted 06-01-2026

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 31, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Final safety, efficacy and biomarker results from the first-in-human study of oncolytic virus RP2 alone and in combination with nivolumab for advanced solid tumors 2504. RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study Joseph J. Sacco (The Clatterbridge ...

Immune Monitor - May 2026

By SITC Communications posted 06-01-2026

A Message from the President The pace of discovery in cancer immunotherapy continues to accelerate, creating both extraordinary opportunity and an urgent need for collaboration. For more than 40 years, the Society for Immunotherapy of Cancer (SITC) Annual Meeting has helped drive these conversations by convening the global immuno-oncology community around the latest advances in science, translational research, and clinical development. SITC 2026 , our 41 st Annual Meeting and Pre-Conference Programs, will be held Nov. 4̶–8 in Phoenix, AZ and virtually. SITC 2026 will bring together researchers, clinicians, government and industry leaders for an ...

2026 ASCO Annual Meeting Scientific Highlights - May 30

By Thomas Martin posted 05-31-2026

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 30, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Tumor-specific MHC-II as a prospective biomarker of response to perioperative chemoimmunotherapy for gastric cancer 2513. Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive /MHC-II negative locally advanced GC/GEJC: A prospective randomized, open-label, biomarker-driven, phase 2 trial Xiangdong Cheng, MD (Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China) presented ...

2026 ASCO Annual Meeting Scientific Highlights - May 29

By Thomas Martin posted 05-30-2026

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 29, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Azer-cel, an allogeneic CAR T cell, for relapsed or refractory CD19 + B cell malignancies 7012. Safety and efficacy of Azer-cel, an allogeneic CD19 CAR T for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy Supriya Gupta (University of Minnesota, Minneapolis, MN, USA) reported results from a phase ...

SITC Signs onto ACS CAN Letter Urging Protection of the USPSTF

By SITC Advocacy posted 05-28-2026

The Society for Immunotherapy of Cancer (SITC) joined more than 60 cancer patient and provider organizations in signing onto a coalition letter led by the American Cancer Society Cancer Action Network (ACS CAN) directed to Secretary Kennedy in support of protecting the scientific integrity and evidence-based work of the U.S. Preventive Services Task Force (USPSTF). View the letter in it's entirety at this LINK . View a press release from ACS CAN at this LINK . The USPSTF plays a critical role in cancer prevention and early detection by developing evidence-based recommendations for preventive services, including screenings for breast, cervical, ...

NEW! The Role of Local Immunotherapy in the Treatment of Cancer

By JITC Publications posted 05-27-2026

Edited by Tanja D. de Gruijl, PhD and Howard Kaufman, MD, FACS While local immunotherapy has the potential to deliver high doses of immune potentiating agents with limited systemic toxicity, clinical development and implementation have been hindered by numerous challenges. This special series addresses the potential promise of local immunotherapy and provides guidance on how to overcome current challenges in local drug development. Authored by leading experts, “The Role of Local Immunotherapy in the Treatment of Cancer” covers various aspects of local immunotherapy and expands upon the topics and concepts presented in the SITC “ Summit on Intralesional ...

SITC Signs onto OVAC Letter Supporting Timely Cancer Research Funding

By SITC Advocacy posted 05-22-2026

The Society for Immunotherapy of Cancer (SITC) joined more than 50 organizations through One Voice Against Cancer (OVAC) in signing a coalition letter to Congress raising concerns about delays and disruptions in federal cancer research funding. View the letter in its entirety at this LINK . The letter, addressed to House and Senate appropriators, expresses appreciation for bipartisan support of the National Institutes of Health (NIH) and the National Cancer Institute (NCI) while highlighting concerns about the slow pace of grant awards, reduced competing grants tied to expanded multi-year funding, and a decline in Notice of Funding Opportunities (NOFOs). ...

SITC 2026 Keynote and Registration Press Release

By Thomas Martin posted 05-20-2026

SITC Announces Keynote Speakers Dr. Ton Schumacher and Dr. Catherine J. Wu at its 41 st Annual Meeting The largest cancer immunotherapy conference featuring the latest research in immuno-oncology MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Ton Schumacher, PhD from the Netherlands Cancer Institute as the Keynote Speaker at its 41 st Annual Meeting and Pre-Conference Programs (SITC 2026) with his presentation “T Cell Recognition of Human Cancer: 'Cracking the Code' ”. SITC also hosts Catherine J. Wu, MD from the Dana-Farber Cancer Institute as the 2026 recipient of the Richard V. Smalley Memorial ...

JITC Digest May 2026

By JITC Publications posted 05-20-2026

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| JITC Meet-the-Editor Session at ASCO| Popular Articles Letter from the Editor Hello JITC Readers, This last month on April 29 th we celebrated with the International Union of Immunological Societies (IUIS) International Day of Immunology . On this day, they focused on regulatory T cells (Tregs) and their role in cancer as well as other immunologic settings. This is timely given the recent Nobel Prize in Physiology or Medicine awarded in late 2025 to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their work identifying and ...

Immune Monitor - April 2026

By SITC Communications posted 05-14-2026

A Message from the President Staying current in immuno-oncology has never been more important—or more complex. With rapid advances across research, clinical practice, and regulation, access to timely, trusted education is essential. That’s where our brand-new Society for Immunotherapy of Cancer (SITC) OnDemand comes in. SITC OnDemand offers a robust, library of expert-led education designed to fit your schedule . Subscribers can access recorded sessions from SITC meetings and programs featuring cutting-edge science, clinical insights, and translational research. Whether you’re catching up on a missed session or revisiting key content, OnDemand helps ...